TNF, tumor necrosis factor, 7124

N. diseases: 2724; N. variants: 31
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease BEFREE To describe the use of tumor necrosis factor-alpha inhibitors (TNFis) among pregnancies ending in a live birth and with a diagnosis of ankylosing spondylitis (AS), Crohn's disease (CD), juvenile idiopathic arthritis (JIA), psoriasis (PsO), psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ulcerative colitis (UC). 30430682 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Biologics against tumor necrosis factor (anti-TNF) have dramatically changed the management of moderate-to-severe ulcerative colitis (UC). 30555013 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE S. boulardii treatment reduced AOM/DSS-induced UC carcinogenesis in mice, as indicated by the reduced tumor load and reduced TNF-α and IL-6 levels in vivo, as well its effects on TNF-α and IL-6 activities in vitro. 31694526 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Twenty-five patients with ulcerative colitis (40% anti-tumor necrosis factor α [TNFα] naive) and 28 patients with Crohn's disease (10.7% anti-TNFα naive, 53.6% having undergone at least one intestinal surgery) were enrolled. 30134234 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE We further demonstrated that GSK2256294, a clinical EPHX2i, reduced the production of IL2, IL12p70, IL10 and TNFα in both ulcerative colitis and Crohn's disease patient-derived explant cultures. 31002701 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE We aimed to compare the treatment persistence rates of infliximab versus adalimumab as first- and second-line tumor necrosis factor antagonists (anti-TNF), to identify factors potentially associated with persistence, and to evaluate reasons for withdrawal in UC patients. 30329067 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Searching terms were ('infliximab', OR 'anti-tumor necrosis factor', OR 'tumor necrosis factor', OR 'tumor necrosis factor alpha antibody', OR 'tumor necrosis factor antibody', OR 'IFX') and ('ulcerative colitis' OR 'UC'). 31562896 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE The long-term effects of anti-TNFα therapy in ulcerative colitis are debatable. 31579961 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Monoclonal antibodies (anti-tumor necrosis factor [TNF] agents, vedolizumab) are the last pharmacotherapeutic option for UC patients before surgery becomes inevitable. 29752633 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE <b>Aims:</b> To evaluate the cost differences between a treatment strategy including tofacitinib (TOFA) vs treatment strategies including adalimumab (ADA), golimumab (GOL), infliximab (IFX), and vedolizumab (VEDO) among all patients with moderate-to-severe ulcerative colitis (UC) (further stratified by patients naïve/exposed to tumor necrosis factor inhibitors [TNFis]). 31012362 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease BEFREE Patients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease duration. 30625408 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Here, a TMDD model is proposed to describe the interaction between infliximab and TNF in UC patients. 31489538 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE An ability to modulate the release of the proinflammatory mediators, such as TNF-α, is an important goal in the development of therapies for the treatment of diseases, such as Crohn's disease and ulcerative colitis, associated with excessive release of inflammatory mediators. 30897368 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE <i>In vitro</i>, we adopted the bone marrow-derived macrophages (BMDMs) as well as BMDMs co-cultured with Caco2 cells to verify the underlying mechanisms and effects of JPQC on UC under TNF-α stimulation. 31210713 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE A rat UC model was induced with trinitro-benzene-sulfonic acid (TNBS), concentrations of the cytokines IL-1α, IL-6, IL-8, IL-1β, and TNF-α were significantly up-regulated and the concentrations of IL-4, IL-10, and IL-13 were significantly down-regulated compared with the control group (P < 0.05). 31102937 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Inhibition of tumor necrosis factor alpha and increased of interleukin 10 by <i>Lactobacillus</i>: a molecular mechanism protection against TNBS-induced ulcerative colitis in chicks. 30821556 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE The non-persistence rate of anti-TNFα therapy was 72.6% and 80.4% in the UC and CD groups, respectively, with discontinuation of medication being the most common reason in both the UC and CD groups (63.9% and 73.3%, respectively). 31098835 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE In the multivariate analysis, having anti-TNF drug levels above the cutoff values [odds ratio (OR) 3.1]) and having UC instead of CD (OR 4) were associated with a higher probability of having mucosal healing. 30426297 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Tumor necrosis factor (TNF)‑α is a central mediator of intestinal inflammation in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease. 29286110 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Compared to high dose corticosteroid use, anti TNF therapy is associated with less risk for death in Crohn's disease but no statistical difference in death outcomes in ulcerative colitis. 29535444 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Because anti⁻tumor necrosis factor therapy is the mainstay for the treatment of moderate-to-severe inflammatory bowel disease; including Crohn's disease and ulcerative colitis, and because testosterone therapy in hypogonadal men with chronic inflammatory conditions reduce tumor necrosis factor-alpha (TNF-α), IL-1β, and IL-6, we suggest that testosterone therapy attenuates the inflammatory process and reduces the burden of disease by mechanisms inhibiting inflammatory cytokine expression and function. 30558178 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE A cohort of 149 moderately to severely active UC and CD patients who failed or showed intolerance to at least two TNF antagonists participated in a medical need program and received vedolizumab in 37 Belgian centers (April-September 2015). 29774158 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease. 30054143 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis (AS), psoriasis (Ps) and/or psoriatic arthritis (PsA) and may be administered off-label to treat disseminated granuloma annulare, systemic lupus erythematosus and systemic sclerosis. 28837372 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease BEFREE Eight functional SNPs were associated with anti-TNF response either among patients with CD (TLR5 (rs5744174) and IFNGR2 (rs8126756)), UC (IL12B (rs3212217), IL18 (rs1946518), IFNGR1 (rs2234711), TBX21 (rs17250932) and JAK2 (rs12343867)) or in the combined cohort of patient with CD and UC (IBD) (NLRP3 (rs10754558), IL12B (rs3212217) and IFNGR1 (rs2234711)) (P<0.05). 28139755 2018